Delivery Order SPE2DB22D1106-SPE2DB25FFEG2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $16,297.57 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $1,871.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order is issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $13,067.60 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens under a firm fixed price contract. The order is scheduled for completion by August 8, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and represents a relatively small-value transaction...
- The Defense Logistics Agency awarded a delivery order valued at $10,128.30 to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens. This is a firm fixed-price delivery order with a completion date of August 21, 2025, issued under a competitive procurement with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,785.59 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens on July 18, 2025, with completion scheduled for July 21, 2025. This competitively awarded, firm fixed-price delivery order represents part of AmerisourceBergen's broader pharmaceutical supply operations supporting federal medical procurement needs. The company, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a $1,298.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside contract, indicating open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a $17,564.19 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within the company's...
- The Defense Logistics Agency awarded a $2,889.13 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 30, 2025, with completion targeted for July 31, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order for pharmaceutical supply to support federal healthcare needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFEG2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,235.08 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on August 20, 2025, with an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order was placed without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999 and running through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen supplies a broad range of medications, vaccines, and medical supplies to support military healthcare programs and other federal healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 8/20/25 |